公开(公告)号：US20230404921A1

公开(公告)日：2023-12-21

申请号：US18250942

申请日：2021-10-29

Applicant: ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY

Inventor： Calum DRUMMOND ,  Brendan Paul DYETT ,  Charlotte CONN ,  Haitao YU

IPC: A61K9/127 ,  A61K47/14 ,  A61K47/10 ,  A61K31/4196 ,  A61K31/7048 ,  A61K31/496 ,  A61K31/4409 ,  A61K31/133 ,  A61K31/7036 ,  A61K31/4965 ,  A61K31/43 ,  A61K38/14 ,  A61K31/407 ,  A61P31/04 ,  A61K31/431

CPC classification number: A61K9/1271 ,  A61K47/14 ,  A61K47/10 ,  A61K31/4196 ,  A61K31/7048 ,  A61K31/496 ,  A61K31/4409 ,  A61K31/133 ,  A61K31/7036 ,  A61K31/4965 ,  A61K31/43 ,  A61K38/14 ,  A61K31/407 ,  A61P31/04 ,  A61K31/431

Abstract: The present disclosure provides for a non-lamellar lyotropic liquid crystalline phase particle which is useful for the delivery of active agents to treat gram-negative bacterial and/or fungal infections. The non-lamellar lyotropic liquid crystalline phase particle is shown to provide benefits in delivery of the active agents through a fusion event with the gram-negative bacteria outer membrane or fungi outer layer.